Natera, Inc. (NASDAQ:NTRA) Insider Sells $117,861.51 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 663 shares of the stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

John Fesko also recently made the following trade(s):

• On Monday, December 23rd, John Fesko sold 669 shares of Natera stock. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40.

Natera Trading Down 1.3 %

Shares of NASDAQ:NTRA opened at $172.82 on Friday. Natera, Inc. has a 1-year low of $67.33 and a 1-year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The business’s 50 day moving average is $167.56 and its 200-day moving average is $140.02.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.95) earnings per share. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Chartwell Investment Partners LLC increased its position in Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after acquiring an additional 11,362 shares in the last quarter. Cerity Partners LLC grew its holdings in Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after acquiring an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Natera during the 3rd quarter valued at $385,000. Everence Capital Management Inc. acquired a new position in shares of Natera in the 4th quarter valued at $573,000. Finally, First Turn Management LLC acquired a new position in shares of Natera in the 3rd quarter valued at $19,760,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. The Goldman Sachs Group lifted their target price on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. JPMorgan Chase & Co. lifted their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Guggenheim boosted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. TD Cowen raised their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Morgan Stanley boosted their price objective on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.